First Trust Direct Indexing’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-2,770
Closed -$1.4M 425
2024
Q3
$1.4M Buy
2,770
+583
+27% +$283K 0.08% 267
2024
Q2
$1.07M Buy
2,187
+121
+6% +$60.7K 0.07% 299
2024
Q1
$1.12M Buy
2,066
+377
+22% +$206K 0.08% 275
2023
Q4
$937K Sell
1,689
-161
-9% -$75.6K 0.08% 277
2023
Q3
$809K Sell
1,850
-148
-7% -$73.8K 0.09% 261
2023
Q2
$1M Buy
1,998
+34
+2% +$16.3K 0.11% 211
2023
Q1
$982K Buy
1,964
+103
+6% +$49.3K 0.12% 214
2022
Q4
$759K Buy
1,861
+231
+14% +$89.7K 0.1% 270
2022
Q3
$531K Buy
1,630
+150
+10% +$55.1K 0.08% 329
2022
Q2
$519K Sell
1,480
-42
-3% -$17.1K 0.07% 343
2022
Q1
$833K Buy
1,522
+120
+9% +$63.1K 0.1% 254
2021
Q4
$923K Sell
1,402
-171
-11% -$107K 0.12% 205
2021
Q3
$978K Buy
1,573
+17
+1% +$11.4K 0.14% 178
2021
Q2
$983K Buy
1,556
+464
+42% +$256K 0.15% 177
2021
Q1
$534K Buy
1,092
+11
+1% +$5.51K 0.14% 195
2020
Q4
$540K Buy
+1,081
New +$484K 0.15% 175

Other funds holding IDXX

First Trust Direct Indexing's IDXX Position: Q4 2024 in Review

First Trust Direct Indexing sold out of Idexx Laboratories (IDXX) in Q4 2024, closing a stake of 2,770 shares — an estimated $1.4M sold.

First Trust Direct Indexing first reported a position in IDXX in Q4 2020 and held it in 16 quarters. The position peaked at $1.4M in Q3 2024. 1,123 funds tracked by Wall St. Rank hold IDXX as of Q4 2024.

  • First Trust Direct Indexing reported no remaining Idexx Laboratories position as of Q4 2024 after selling out during the quarter.
  • First Trust Direct Indexing sold 2,770 Idexx Laboratories shares in Q4 2024, an estimated $1.4M.
  • First Trust Direct Indexing first reported a position in Idexx Laboratories in Q4 2020 and held it in 16 quarters.
  • First Trust Direct Indexing's Idexx Laboratories position peaked at $1.4M in Q3 2024.
  • 1,123 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2024.

Based on First Trust Direct Indexing's 13F filing for Q4 2024.